The Global Atrial Fibrillation Market is estimated to be worth USD 7.8 Billion in 2021 and is expected to reach USD 15.83 Billion by 2026, growing at a CAGR of 15.2%.
According to the U.S. CDC, around 12.1 million people in the U.S. are estimated to have atrial fibrillation by 2030. The growing geriatric population, increasing sedentary lifestyle, rising obese population, heavy drinking, and growing disorders leading to heart conditions such as hypertension, atherosclerosis, etc is the major factors raising the prevalence of atrial fibrillation. Furthermore, rising awareness of minimally invasive surgery, healthcare spending, and healthcare tourism is expected to further escalate market growth. However, lack of professional skill and stringent Government regulations of the healthcare sector is anticipated to hinder the market growth.
Rising pharmaceutical innovations coupled with increasing healthcare economies in emerging countries is expected to create new opportunities to the market.
The Global Atrial Fibrillation Market is segmented based on Products, Type, and Geography.
Some of the companies covered in this report are Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Sanofi Aventis, and Abbott Laboratories., etc.
The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
The report offers a comprehensive evaluation of the Global Atrial Fibrillation Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel within the industry.
The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of COVID-19 on the market is also featured in the report.
The report also includes the regulatory scenario of the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules & regulations imposed on this sector across various geographies.
The report also contains the competitive analysis using Positioning Quadrants, the analyst's proprietary competitive positioning tool.
Market Dynamics
According to the U.S. CDC, around 12.1 million people in the U.S. are estimated to have atrial fibrillation by 2030. The growing geriatric population, increasing sedentary lifestyle, rising obese population, heavy drinking, and growing disorders leading to heart conditions such as hypertension, atherosclerosis, etc is the major factors raising the prevalence of atrial fibrillation. Furthermore, rising awareness of minimally invasive surgery, healthcare spending, and healthcare tourism is expected to further escalate market growth. However, lack of professional skill and stringent Government regulations of the healthcare sector is anticipated to hinder the market growth.
Rising pharmaceutical innovations coupled with increasing healthcare economies in emerging countries is expected to create new opportunities to the market.
Market Segmentation
The Global Atrial Fibrillation Market is segmented based on Products, Type, and Geography.
- By Products, the market is classified as surgical devices, non-surgical devices, and drugs. Amongst all, the surgical devices segment is estimated to hold the highest market share during the forecast period.
- By Type, the market is classified as paroxysmal, persistent, and long-term persistent. Amongst all, the paroxysmal segment is estimated to hold the highest market share during the forecast period.
- By Geography, North America is projected to lead the market.
Recent Developments
- The U.S. FDA has granted Tempus Inc. approval for its ECG Analysis Platform. Developed in collaboration with Geisinger, it helps clinicians identify patients at increased risk of developing atrial fibrillation (AF) or atrial flutter. - 24th March 2021.
- Medtronic plc announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). - 4th March 2021.
Company Profiles
Some of the companies covered in this report are Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Sanofi Aventis, and Abbott Laboratories., etc.
Competitive Quadrant
The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Why buy this report?
The report offers a comprehensive evaluation of the Global Atrial Fibrillation Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel within the industry.
The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of COVID-19 on the market is also featured in the report.
The report also includes the regulatory scenario of the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules & regulations imposed on this sector across various geographies.
The report also contains the competitive analysis using Positioning Quadrants, the analyst's proprietary competitive positioning tool.
Report Highlights
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Atrial Fibrillation Market
What is the estimated value of the Global Atrial Fibrillation Market?
What is the growth rate of the Global Atrial Fibrillation Market?
What is the forecasted size of the Global Atrial Fibrillation Market?
Who are the key companies in the Global Atrial Fibrillation Market?
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Influencers
5 Market Analysis
6 Global Atrial Fibrillation Market, By Product
7 Global Atrial Fibrillation Market, By Application
8 Global Atrial Fibrillation Market, By Geography
9 Competitive Landscape
10 Company Profiles
11 Appendix
Companies Mentioned
- Abbott Laboratories
- Johnson & Johnson
- MicroPort Scientific Corporation
- Boston Scientific Corporation
- St. Jude Medica. Inc.
- Medtronic plc
- Biotronik SE & Co. KG
- Siemens AG
- AtriCure Inc.
- Biosense Webste. Inc.
- CardioFocu. Inc.
- CathEffects Inc.
- CathRx Ltd.
- EndoPhotoni. Inc.
- Japan Lifeline Co.
- Osypka AG
- Pioneer Medical Devices AG
- GE Healthcare
- TZ Medica. Inc.
- Boehringer Ingelheim GmbH
